Pharmacogenomics in cancer supportive care: key issues and future directions

Ethics of artificial intelligence in supportive care in cancer

“…The use of AI can provide decision support to patients and clinicians in delivering personalised supportive care in cancer 2 . This includes, for example, optimising anticancer drug dosing to avoid toxicity and selecting the appropriate supportive care in cancer drug dosing using a patient's pharmacogenomic profile 3 . AI enables a more accurate prediction of toxicities such as emesis by including patient‐related factors added to the emetogenicity of cancer treatment.…”

The application of “Omics” to accelerate precision medicine in Supportive Care in Cancer

“…But the number of patients affected by mutations impacting cancer drug metabolism is small in comparison to the numbers of individuals who have markedly symptomatic or cancer therapy-limiting toxicities. Nonetheless, variations in pharmacogenes can also impact response to several non-oncologic treatments, dozens of which are used as supportive therapies in cancer patients (e.g., antidepressants, antiemetics, antifungals, and opioids) [11]. Novel, albeit expensive, immunotherapies and targeted treatments, coupled with supportive care, are potentially financially toxic and deleterious to successful outcomes, especially if done in the absence of a proper assessment of patient risk.…”